GU Cancers 2022 | Futibatinib plus pembrolizumab for the treatment of advanced or metastatic urothelial carcinoma

Vadim Koshkin, MD, University of California San Francisco, San Francisco, CA, discusses a Phase II trial exploring the treatment of advanced or metastatic urothelial carcinoma (mUC) with the pan-FGFR inhibitor, futibatinib, plus the anti-PD1, pembrolizumab. Patients with FGFR alterations can be reliably targeted with agents such as futibatinib which have demonstrated synergy when combined with immune checkpoint inhibitors such pembrolizumab. Dr Koshkin explains the possibility of synergy even in patients without FGFR alterations sue to changes generated by FGFR inhibition in the tumor microenvironment (TME) that may induce vulnerability to immune checkpoint inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.